FTC Accuses Hims & Hers of Deceiving Patients and Sharing Health Data with Big Tech: How Markets React?

The Federal Trade Commission (FTC), along with California and Utah, has sued telehealth platform Hims & Hers Health for allegedly charging patients for prescription subscriptions without their consent and secretly sharing their sensitive health information with tech companies including Meta and Snap. The complaint alleges the platform advertised 'free consultations' and displayed 'Pay $0 today' on intake forms, then enrolled patients in recurring subscriptions as soon as a healthcare provider wrote a prescription—without giving them the chance to review or decline the treatment. Customer complaints cited in the lawsuit include one patient who was charged $897 before ever speaking to a healthcare professional and another who was charged $147 for a three-month supply of Lexapro after stating they were 'open to' medication on an intake form. Regulators allege the company made cancellation deliberately difficult, burying the option behind an 'Add/remove items from order' button that never used the word 'cancel.' The lawsuit claims the company advertised monthly or quarterly refill schedules but actually processed refill charges 10 days earlier than consumers would reasonably expect, requiring cancellations two days before that early processing date. Hims & Hers is also accused of sharing patients' sensitive health information—including conditions like erectile dysfunction, premature ejaculation, and hair loss—with advertising platforms despite promising users the service was '100% online, private and secure.' The company called the claims 'baseless' on X, vowing to fight them and stating this is not enforcement grounded in consumer protection but an effort to generate headlines at their expense. Hims & Hers Health Inc stock plummeted more than 11% after the lawsuit was announced. The company reports 2.6 million subscribers for personal health, skin care, hair loss treatments, and weight-loss management, up 9% year-over-year. Hims & Hers has been closely watched as a major player in the market for compounded GLP-1 weight-loss medications. Regulators have intensified oversight of telehealth providers, and this lawsuit could become one of the most significant consumer-protection cases in the telehealth space, deciding how online healthcare companies design patient intake forms, subscription billing, cancellation flows, and advertising technology going forward. The company's next earnings report is scheduled for August 10. Much of Hims & Hers' marketing strategy centers on celebrity endorsements and influencer marketing, including partnerships with high-profile figures like Kristen Bell, Rob Gronkowski, Miley Cyrus, and Alex Rodriguez. The FTC complaint notes that Hims has relied heavily on paid social media influencers, particularly on YouTube, and that some influencers described Hims' services as 'discreet,' reinforcing the company's privacy-focused marketing.

Markets will be sensitive to this development: Hims & Hers' stock performance could reflect investor skepticism about telehealth platforms that secretly charge patients and share health data. Such cases may prompt the industry to re-examine transparency standards and raise questions about how cautiously major tech companies should handle health data.